Overview
- The offer values Amicus at $14.50 per share, a roughly 33% premium to its prior close, with unanimous approval from both boards.
- Closing is targeted for the second quarter of 2026, subject to Amicus shareholder approval and customary antitrust clearances.
- The acquisition adds Galafold for Fabry disease and Pombiliti plus Opfolda for late-onset Pompe, plus a Phase 3 FSGS candidate, with the marketed drugs generating about $599 million over the past year.
- A litigation settlement on Galafold with Aurobindo and Lupin leads Amicus to expect no U.S. generics until early 2037.
- BioMarin plans to fund the transaction with cash and approximately $3.7 billion of non-convertible debt.